전체 프로그램

ADC 890 · Antibody 4071 · CGT 2714 · 다음 갱신 D-3 · 마지막 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved2,403 programs
CGTLimited DatastaleGerman Cancer Research CenterPhase 1

Donor-derived CD34+ HSC with CRISPR/Cas9-mediated CD33 deletion (Donor-derived CD34+ HSC with CRISPR/Cas9-mediated CD33 deletion)

Relapsed/Refractory Acute Myeloid Leukemia (AML) · CD33

#CD33#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
AntibodyLimited DatastaleTesaro, Inc.Phase 3

TSR-042 (Dostarlimab, Dostarlimab (TSR-042))

Ovarian Neoplasms; Ovarian, Fallopian Tube and Primary Peritoneal Carcinoma · Ovarian Neoplasms

#OvarianNeoplasms#Antibody#Phase3#monoclonal-antibody#Ovarian+2
Trials 1Status Recruiting
AntibodyLimited DatastaleTokyo UniversityPhase 3

Double-Blind Rituximab (Double-Blind Rituximab)

Scleroderma, Systemic; Skin Sclerosis · Scleroderma, Systemic

#SclerodermaSystemic#Antibody#Phase3#monoclonal-antibody#Scleroderma+3
Trials 1Status Active
AntibodyLimited DatastaleAbbViePhase 3

adalimumab (Humira, Double-blind adalimumab)

Rheumatoid Arthritis · Rheumatoid Arthritis

#RheumatoidArthritis#Antibody#Phase3#monoclonal-antibody#AbbVie
Trials 1Status Active
AntibodyLimited DatastaleQilu Hospital of Shandong Unive…Preclinical

Doublet or triplet chemotherapy combined with cetuximab (Doublet or triplet chemotherapy combined with cetuximab)

Colon Cancer · Colon Cancer

#ColonCancer#Antibody#Preclinical#monoclonal-antibody#Qilu
Trials 1Status Active
AntibodyLimited DatastaleAbbViePreclinical

adalimumab (Humira, Dovobet, neotigason, etanercept, adalimumab. infliximab)

Psoriasis · Psoriasis

#Psoriasis#Antibody#Preclinical#monoclonal-antibody#AbbVie
Trials 1Status Active
AntibodyLimited DatastaleJanssenPreclinical

daratumumab (Darzalex, Dratumumab / Hyaluronidase Injection [Darzalex Faspro])

Light Chain (AL) Amyloidosis · Light Chain (AL) Amyloidosis

#LightChainALAmyloidosis#Antibody#Preclinical#monoclonal-antibody#Janssen
Trials 1Status Recruiting
AntibodyLimited DatastaleSichuan Kelun-Biotech Biopharma…Phase 1

Drug: Tagitanlimab Drug: Capecitabine (Drug: Tagitanlimab Drug: Capecitabine)

Advanced Solid Tumors · Advanced Solid Tumors

#AdvancedSolidTumors#Antibody#Phase1#monoclonal-antibody#Sichuan
Trials 1Status Recruiting
CGTLimited DatastaleBeijing Boren HospitalPhase 1

Dual CD33/CLL1 CAR T (Dual CD33/CLL1 CAR T)

Acute Myeloid Leukemia · CD33

#CD33#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Discontinued
CGTLimited DatastaleChinese PLA General HospitalPhase 2

Dual Specificity CD38 and bcma CAR-T Cells (Dual Specificity CD38 and bcma CAR-T Cells)

Multiple Myeloma · BCMA

#BCMA#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 1Status Active
CGTLimited DatastaleEssen BiotechPhase 2

Dual-Target Antigen-Selected CAR-NK (Dual-Target Antigen-Selected CAR-NK)

Cancer; Breast Cancer · MET

#MET#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleBeijing BiotechPhase 2

EB-DT-CAR-NK (Dual-target CAR-NK cells, Dual-target CAR-NK cells (EB-DT-CAR-NK))

Breast Cancer (Locally Advanced or Metastatic); HER2-positive Breast Cancer · HER2

#HER2#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleBeijing GoBroad HospitalPhase 1

Dual-targeting BCMA-CD19 CAR-T cell infusion (Dual-targeting BCMA-CD19 CAR-T cell infusion)

Relapsed or Refractory Multiple Myeloma (RRMM) · CD19

#CD19#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
CGTLimited DatastaleSichuan UniversityPhase 1

Dual-targeting CLDN18.2 and PD-L1 CAR-T cells (Dual-targeting CLDN18.2 and PD-L1 CAR-T cells)

Advanced Solid Tumor · PD-L1

#PD-L1#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
CGTLimited DatastaleSichuan UniversityPhase 1

Dual-targeting HER2 and PD-L1 CAR-T cells (Dual-targeting HER2 and PD-L1 CAR-T cells)

Peritoneal Carcinoma Metastatic; Pleural Effusion, Malignant · HER2

#HER2#CGT#Phase1#cell-gene-therapy#CAR-T+5
Trials 1Status Recruiting
CGTLimited DatastaleSichuan UniversityPhase 1

Dual-targeting VEGFR1 and PD-L1 CAR-T cells (Dual-targeting VEGFR1 and PD-L1 CAR-T cells)

Malignant Peritoneal Effusion; Malignant Ascites · EGFR

#EGFR#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Active
CGTLimited DatastaleSichuan UniversityPhase 1

Dual-targeting VEGFR1/PD-L1 CAR-T cells (Dual-targeting VEGFR1/PD-L1 CAR-T cells)

Malignant Peritoneal Effusion; Malignant Ascites · EGFR

#EGFR#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleUniversity of Kansas Medical Ce…Phase 1

DuoCAR20.19.22-D95 (DuoCAR20.19.22-D95)

B-Cell Non-Hodgkin Lymphoma; B-cell Acute Lymphoblastic Leukemia · B-Cell Non-Hodgkin Lymphoma

#B-CellNon-HodgkinLymphoma#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
AntibodyLimited DatastaleCelgenePhase 2

Duravalumab (Duravalumab)

Carcinoma, Non-Small-Cell Lung · Carcinoma, Non-Small-Cell Lung

#CarcinomaNon-Small-CellLung#Antibody#Phase2#monoclonal-antibody#Carcinoma+2
Trials 1Status Active
AntibodyLimited DatastaleKyoto Breast Cancer Research Ne…Phase 2

Durvalmab&Tremelimumab&Fulvestrant (Durvalmab&Tremelimumab&Fulvestrant)

Breast Cancer · Breast Cancer

#BreastCancer#Antibody#Phase2#monoclonal-antibody#Kyoto
Trials 1Status Discontinued

72 / 121 pages

← PreviousNext →